Kite, A Gilead Company, Received FDA Approval Of Manufacturing Process Change Resulting In Reduced Median Turnaround Time For Yescarta CAR T-cell Therapy

-2.70% Post

Gilead Sciences, Inc.

GILD

109.06

-2.70%

0.00% Post

– New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days –

– Continues to Support Kite's Industry-Leading Overall Turnaround Time and Reliability –

– Time to Treatment is a Critical Factor for CAR T-cell Therapy Patients –

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.